Shape-shifting cells may explain why APOE4 carriers are at greater risk of cerebrovascular disease. In the 24 September Cell, scientists led by Joel Blanchard at the Icahn School of Medicine at Mount ...

Can brain amyloid reduction be used as a surrogate biomarker of clinical benefit? This is a hotly debated question in the field (see Dec 2024 discussion). A recent post hoc analysis of Phase 3 ...

To scientists peering through a microscope, lipofuscin presents as nuisance, interfering with immunohistochemical analysis. Could this poorly characterized, autofluorescent debris shine light on both ...

CAR-T cell therapy has practically become a household name, given its success in taking down blood cancers. The chimeric antigen receptors used in this type of cell therapy are designed to sic killer ...

White-matter hyperintensities, a sign of damage to the brain’s vasculature, are common on MRI scans of people with Alzheimer’s disease. Do they indicate an independent vascular co-pathology, or are ...

Amyloid plaques drive the spread of tangles throughout a person’s brain, but much about this process remains mysterious. At this year’s AD/PD conference in Copenhagen, Denmark, speakers showed PET ...

The notion that lithium might treat Alzheimer’s was revived last year when scientists reported that the brains of people and mice with amyloid pathology are deficient in the metal ion, and that the ...

Once more than 4 percent of tau molecules in a person’s blood are phosphorylated at residue 217, the clock starts ticking—toward the first symptoms of Alzheimer’s disease, that is. How long it might ...

According to a recent study, the view that Alzheimer’s disease damages the brain irreversibly might need to change. In December 22 Cell Reports Medicine online, scientists led by Andrew Pieper of Case ...

On November 24, Novo Nordisk announced that the GLP-1 mimetic semaglutide had failed to slow progression of Alzheimer’s disease in two Phase 3 trials. Even though the cat was out of the bag, ...

Transferrin-receptor shuttles distribute antibody cargo throughout the parenchyma, steering clear of ARIA-provoking vascular amyloid. Trontinemab is enrolling Phase 3 for early AD, announces plans for ...

At the 19th AD/PD conference, Alzforum reporters wrote 15 summaries of findings across both diseases. From a step toward finally having an α-synuclein PET tracer to a major focus on Trem2 as a drug ...